6th ESO-ESMO-RCE Clinical update on RARE ADULT SOLID CANCERS
Chairs: J.Y. Blay, FR - P.G. Casali, IT - R. Stahel, CH
The “ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers” is an educational effort held on an annual basis and conceived to strengthen the education of medical professionals willing to devote their career to rare cancers.
Despite being rare as single entities, rare adult solid cancers account for as many as 15% of all new cancer cases, thus being the main group within rare cancers in general. The definition of rare cancers by the RARECARE project and the list of the 10 “families” of rare adult solid cancers gave rise to shape the sessions of this course:
- Head & neck cancers
- Sarcomas
- Rare thoracic tumors
- Neuroendocrine tumors
- Central nervous system neoplasms
- Rare female genital cancers
- Endocrine gland tumors
- Digestive rare cancers
- Rare urological and male genital tumors
- Rare skin cancers & non-cutaneous melanoma
Since ‘networking’ and ‘multidisciplinarity’ are the two main keywords to improve the quality of care of rare cancers, ESO has decided to develop the programme of this course in collaboration with other European initiatives in this field and to give its contribution to tackle the rare cancer issue. The 6th ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers was conceived in the context of, and supported by, EURACAN, the European Reference Network on rare adult solid cancers. The Faculty has been largely selected from EURACAN, also with the aim of letting this educational effort closely interact with its networking activities.
Optimal management of rare adult solid cancers poses specific diagnostic and therapeutic challenges. The sessions of the course have been designed to address the needs of clinical oncologists wanting an update on recent advancements on these tumours.
The course will be held online and we have done our best to design a programme enabling participants to attend according to their own schedule. There has been a mixture of pre-recorded sessions and live sessions for Q&A and clinical case discussions with faculty members and moderators.
Paolo Casali
On behalf of the co-Chairs
INFORMATION
The course will be carried out in two different steps:
Step 1: Pre-recorded sessions will be made available from 16 December 2021 and will remain on the e-ESO website. You will be able to see all the sessions in your own time and send questions that will be selected for discussion during Step 2 of the course. Please remember that registration to the full course is free but mandatory in order to gain access to the sessions.
Step 2: Live sessions with an introductory round table on rare cancers in general, clinical case presentations and Q&A discussions with moderators and speakers will be held on 29 and 30 January 2022 (please see the detailed programme). During the Q&A sessions, speakers will answer and discuss a number of selected questions received in advance via email (see below for instructions) and/or during the live streaming via chat.
Q&A sessions: You are encouraged to send questions in advance, as long as you listen to the recorded sessions. The moderators will select questions to be answered during the live streaming. Questions should be sent to raretumours@eso.net, no later than 18 January 2022. Please indicate the session title and speaker your question refers to.
All the contents will be recorded and will remain accessible via the e-ESO website until January 2024 (registration to access the contents will remain open).
IDEAL PARTICIPANT'S PROFILE
- Medical degree
- Specialization/residency in medical oncology, radiation oncology, surgical oncology or equivalent
LEARNING OBJECTIVES
Provide an update on the latest developments in the area of rare adult solid rare cancers, with a background perspective on state-of-the-art and evidence based practice.
REGISTRATION
Registration for the course is required but free (you can find the registration link on the right).
Registration will be confirmed by e-mail.
OFFICIAL LANGUAGE
The official language is English. Translation is not provided.
CME ACCREDITATION CERTIFICATES
Participants will be issued a certificate of attendance (minimum attendance: 75% of the entire course). An online evaluation questionnaire and learning assessment test will need to be completed in order to get the certficate that will be issued by email.
Application for CME recognition has been submitted to the Accreditation Council of Oncology in Europe (ACOE) and 19 CME credits have been granted to this event. The American Medical Association (AMA) and the Accreditation Council for Continuous Medical Education (ACCME) designate this type of educational activity for a maximum of 1 AMA PRA category 1 credits per hour of activity.
CME credits will be available until 30 January 2024.
ESCO CREDITS
The Course enables ESCO students to earn ESCO credits and therefore access more ESCO benefits. Full and active participation in the Course earns participants 21 ESCO credits.
Visit www.esco.org for information on how to join ESCO.
ORGANISING SECRETARIAT
Marina Fregonese - Event Organiser - mfregonese@eso.net
Dolores Knupfer - Event Organiser - dknupfer@eso.net
Mariachiara Deleo - e-ESO Assistant - mdeleo@eso.net
Francesca Marangoni - e-ESO Executive Manager - fmarangoni@eso.net
Follow us on Facebook, Twitter and Instagram: #e_ESO
Instructions on how to use e-ESO to participate in this event
The course will remain available until JANUARY 2024.
Update on RARE THORACIC CANCERS
| 16/12/2021 |
Mesothelioma
| Expert: | Rolf A. Stahel, CH |
Thymic tumors
| Expert: | Giulia Galli, IT |
Update on SARCOMAS
| 16/12/2021 |
Adult soft tissue sarcomas
| Expert: | Paolo Giovanni Casali, IT |
GIST
| Expert: | Jean-Yves Blay, FR |
Ewing sarcoma and osteosarcoma
| Expert: | Sandra Strauss, UK |
Rare bone and soft tissue sarcomas
| Expert: | Anna Maria Frezza, IT |
Update on HEAD AND NECK CANCERS
| 16/12/2021 |
Laryngeal and hypopharyngeal carcinoma
| Expert: | Cesare Piazza, IT |
Oropharyngeal carcinoma
| Expert: | Vincent Gregoire, FR |
Nasopharyngeal carcinoma
| Expert: | Anthony Chan, CN |
Sinonasal cancers
| Expert: | Lisa Licitra, IT |
Salivary gland tumors
| Expert: | Laura Deborah Locati, IT |
Oral cavity tumors
| Expert: | Christian Simon, CH |
Update on NEUROENDOCRINE TUMORS
| 16/12/2021 |
Thoracic NETs
| Expert: | Martyn Caplin, UK |
Gastroenteropancreatic NETs
| Expert: | Nicola Fazio, IT |
Update on CNS TUMORS
| 16/12/2021 |
Gliomas
| Expert: | Riccardo Soffietti, IT |
Rare CNS tumors
| Expert: | Martin J. Van den Bent, NL |
Update on ENDOCRINE GLAND TUMORS
| 16/12/2021 |
Adrenal cancer
| Expert: | Alfredo Berruti, IT |
Thyroid cancer
| Expert: | Jaume Capdevila, ES |
Hereditary cancer risk syndromes
| Expert: | Nicoline Hoogerbrugge, NL |
Update on DIGESTIVE RARE CANCERS
| 16/12/2021 |
Biliary tumors
| Expert: | Heinz-Josef Klumpen, NL |
Anal carcinoma
| Expert: | Robert Glynne-jones, UK |
Peritoneal mesothelioma and pseudomyxoma
| Expert: | Marcello Deraco, IT |
Update on RARE UROGENITAL CANCERS
| 16/12/2021 |
Testicular cancer
| Expert: | Jourik A. Gietema, NL |
Penile cancer
| Expert: | Andrea Necchi, IT |
Update on RARE FEMALE GENITAL CANCERS
| 16/12/2021 |
Non-epithelial ovarian tumors
| Expert: | Isabelle Ray-Coquard, FR |
Trophoblastic tumors
| Expert: | Michael Seckl, UK |
Vulvar and vaginal cancers
| Expert: | Domenica Lorusso, IT |
Update on RARE SKIN TUMORS AND UVEAL MELANOMA
| 16/12/2021 |
Merkel cell carcinoma
| Expert: | Celeste Lebbé, FR |
Cutaneous adnexal malignancies
| Expert: | Stefano Cavalieri, IT |
Uveal melanoma
| Expert: | Martina Angi, IT |
Day 1 LIVE
| 29/01/2022 |
Rare cancers in Europe: what's going on (ROUNDTABLE)
| 29/01/2022 |
Introduction
| Experts: | Fedro Alessandro Peccatori, IT - Rolf A. Stahel, CH |
| Moderators: | Fedro Alessandro Peccatori, IT - Rolf A. Stahel, CH |
Round table: Rare cancers in Europe: what's going on
| Experts: | Jean-Yves Blay, FR - Paolo Giovanni Casali, IT - Kathy Oliver, UK |
Q&A and general discussion
| Experts: | Jean-Yves Blay, FR - Paolo Giovanni Casali, IT - Kathy Oliver, UK - Fedro Alessandro Peccatori, IT - Rolf A. Stahel, CH |
Update on RARE THORACIC CANCERS (Q&A and clinical cases)
| 29/01/2022 |
| Moderators: | Nicolas Girard, FR - Rolf A. Stahel, CH |
Clinical case discussion
| Expert: | Clemence Basse, FR |
Q&A
| Experts: | Clemence Basse, FR - Giulia Galli, IT - Nicolas Girard, FR - Rolf A. Stahel, CH |
Update on SARCOMAS (Q&A and clinical cases)
| 29/01/2022 |
| Moderators: | Jean-Yves Blay, FR - Paolo Giovanni Casali, IT |
Clinical case discussion
| Expert: | Dario Callegaro, IT |
Q&A
| Experts: | Jean-Yves Blay, FR - Dario Callegaro, IT - Paolo Giovanni Casali, IT - Anna Maria Frezza, IT - Sandra Strauss, UK |
Update on HEAD AND NECK CANCERS (Q&A and clinical cases)
| 29/01/2022 |
| Moderators: | Vincent Gregoire, FR - Lisa Licitra, IT |
Clinical case discussion
| Expert: | Carlo Resteghini, IT |
Q&A
| Experts: | Anthony Chan, CN - Vincent Gregoire, FR - Lisa Licitra, IT - Laura Deborah Locati, IT - Cesare Piazza, IT - Carlo Resteghini, IT |
Update on CNS TUMORS (Q&A and clinical cases)
| 29/01/2022 |
| Moderators: | Riccardo Soffietti, IT - Martin J. Van den Bent, NL |
Clinical case discussion
| Expert: | Alessia Pellerino, IT |
Q&A
| Experts: | Alessia Pellerino, IT - Riccardo Soffietti, IT - Martin J. Van den Bent, NL |
Day 2 LIVE
| 30/01/2022 |
Update on NEUROENDOCRINE TUMORS (Q&A and clinical cases)/
| 30/01/2022 |
Clinical case discussion
| Expert: | Katarzyna Blazejczyk, DE |
| Moderators: | Martyn Caplin, UK - Nicola Fazio, IT |
Q&A
| Experts: | Katarzyna Blazejczyk, DE - Martyn Caplin, UK - Nicola Fazio, IT |
Update on ENDOCRINE GLAND TUMORS (Q&A and clinical cases)
| 30/01/2022 |
| Moderators: | Lisa Licitra, IT - Christelle de la Fouchardiere, FR |
Clinical case discussion
| Expert: | Elena Colombo, IT |
Q&A
| Experts: | Alfredo Berruti, IT - Jaume Capdevila, ES - Elena Colombo, IT - Nicoline Hoogerbrugge, NL - Lisa Licitra, IT - Christelle de la Fouchardiere, FR |
Update on DIGESTIVE RARE CANCERS (Q&A and clinical cases)
| 30/01/2022 |
| Moderators: | Filippo De Braud, IT - Lucjan Wyrwicz, PL |
Clinical case discussion
| Expert: | Monica Niger, IT |
Q&A
| Experts: | Filippo De Braud, IT - Marcello Deraco, IT - Robert Glynne-jones, UK - Heinz-Josef Klumpen, NL - Monica Niger, IT - Lucjan Wyrwicz, PL |
Update on RARE UROGENITAL CANCERS (Q&A and clinical cases)
| 30/01/2022 |
| Moderator: | Jourik A. Gietema, NL |
Clinical case discussion
| Expert: | Daniele Raggi, IT |
Q&A
| Experts: | Jourik A. Gietema, NL - Daniele Raggi, IT |
Update on RARE FEMALE GENITAL CANCERS (Q&A and clinical cases)
| 30/01/2022 |
| Moderators: | Fedro Alessandro Peccatori, IT - Michael Seckl, UK |
Clinical case discussion
| Expert: | Stefanie Aust, AT |
Q&A
| Experts: | Stefanie Aust, AT - Fedro Alessandro Peccatori, IT - Isabelle Ray-Coquard, FR - Michael Seckl, UK |
Update on RARE SKIN TUMORS AND UVEAL MELANOMA (Q&A and clinical cases)
| 30/01/2022 |
| Moderators: | Ellen Kapiteijn, NL - Sophie Piperno-Neumann, FR |
Clinical case discussion
| Expert: | Thais Tong, NL |
Q&A
| Experts: | Martina Angi, IT - Stefano Cavalieri, IT - Ellen Kapiteijn, NL - Celeste Lebbé, FR - Sophie Piperno-Neumann, FR - Thais Tong, NL |
CLOSING REMARKS
| Expert: | Paolo Giovanni Casali, IT |
/attachment.e-eso.net/48/694.jpg)
Ocular Oncologist, National Cancer Institute - IRCCS Foundation, Milan, Italy, Milan, Italy
/attachment.e-eso.net/48/2021112404122060.jpg)
Medical University of Vienna, Vienna, Austria
/attachment.e-eso.net/48/2022011310124801.png)
Institut Curie, Paris, France
/attachment.e-eso.net/48/2d9ff457-7833-4568-b14f-b4c5d1ba3c40.jpg)
ASST Spedali Civili, Brescia, Italy
/attachment.e-eso.net/48/36141816-e67f-4b8a-93e4-b304860b4e26.jpg)
Université Claude Bernard Lyon & Centre Léon Bérard, Lyon, France
/attachment.e-eso.net/48/2022011412075412.jpg)
Clinical Investigator, Emovis Dedicated Study Site, Berlin, Germany
/attachment.e-eso.net/48/2022011402412339.jpg)
Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
/attachment.e-eso.net/48/2021050608280078.jpg)
Vall d'Hebron University Hospital, Barcelona, Spain
/attachment.e-eso.net/48/2021101912462441.jpg)
Royal Free Hospital, London, United Kingdom
/attachment.e-eso.net/48/b5e64e6b-856f-4ef2-b5c5-107c4e97aff7.jpg)
National Cancer Institute - IRCCS Foundation, Milan, Italy
/attachment.e-eso.net/48/2021102011335320.jpg)
IRCCS Foundation - National Cancer Institute, Milan, Italy
/attachment.e-eso.net/48/9a241fd0-c0ee-4992-aa6a-bd2c37cd1faf.png)
The Chinese University of Hong Kong, Hong Kong SAR, China
/attachment.e-eso.net/48/2021111204471666.jpg)
National Cancer Institute - IRCCS Foundation, Milan, Italy
/attachment.e-eso.net/48/2021050608300505.jpeg)
National Cancer Institute, Milan, Italy
/attachment.e-eso.net/48/917.jpg)
Centre Leon Berard, Lyon, France
/attachment.e-eso.net/48/2021050608315248.jpg)
IRCCS Foundation, National Institute of Cancer, Milan, Italy
/attachment.e-eso.net/48/2d38bf14-08f7-4e2e-b8ca-e9b99ede8b7e.png)
European Institute of Oncology, Milan, Italy
/attachment.e-eso.net/48/913.jpg)
National Cancer Institute - IRCCS Foundation, Milan, Italy
/attachment.e-eso.net/48/2021101912492556.jpg)
National Cancer Institute - IRCCS Foundation, Milan, Italy
/attachment.e-eso.net/48/d6db8f33-6344-444f-988e-1434dd33fe21.png)
University Medical Center Groningen, Groningen, The Netherlands
/attachment.e-eso.net/48/7a5e4072-6a5d-4e46-aef2-896fea17ef83.jpg)
Institut Curie, Paris, France
/attachment.e-eso.net/48/31.jpg)
Mount Vernon Centre for Cancer Treatment, Northwood, Middlesex, United Kingdom
/attachment.e-eso.net/48/687.jpg)
Centre Leon Berard, Lyon, France
/attachment.e-eso.net/48/2021101902142270.jpg)
Radboud University Medical Center, Nijmegen, The Netherlands
/attachment.e-eso.net/48/2021101902153933.jpg)
Leiden University Medical Center, Leiden, The Netherlands
/attachment.e-eso.net/48/2021101912452440.jpg)
Amsterdam UMC, Amsterdam, The Netherlands
/attachment.e-eso.net/48/31814390-a10f-4fe0-95d5-5ceddf02e7ac.png)
Saint Louis Hospital, Paris, France
/attachment.e-eso.net/48/273.jpg)
Medical Oncologist, National Cancer Institute - IRCCS Foundation, Milan, Italy
/attachment.e-eso.net/48/591.jpg)
Medical oncologist, University of Pavia; Istituti Clinici Scientifici IRCCS Maugeri, Pavia, Italy
/attachment.e-eso.net/48/2021042103142543.jpg)
Gynaecological Oncology Unit, Humanitas San Pio X; Humanitas University, Milan, Italy
/attachment.e-eso.net/48/91.jpg)
IRCCS Ospedale San Raffaele, Milano, Italy
/attachment.e-eso.net/48/2021111204455157.jpg)
National Cancer Institute - IRCCS Foundation, Milan, Italy
/attachment.e-eso.net/48/2021121712423767.jpg)
International Brain Tumour Alliance - IBTA, Tadworth, Surrey, United Kingdom
/attachment.e-eso.net/48/2021032304451963.jpg)
European Institute of Oncology, Milan, Italy
/attachment.e-eso.net/48/2020112509053558.jpg)
City of Health and Science University Hospital, Turin, Italy
/attachment.e-eso.net/48/714832e9-8a81-4c2e-9438-553294f068dd.jpg)
Università degli Studi di Brescia, Brescia, Italy
/attachment.e-eso.net/48/2021101902130169.jpg)
Curie Institute, Paris, France
/attachment.e-eso.net/48/2022011310272007.jpg)
IRCCS San Raffaele Hospital, Milan, Italy
/attachment.e-eso.net/48/2021050608181783.jpg)
Léon Bérard Center, Lyon, France
/attachment.e-eso.net/48/2022011404140109.JPG)
Medical oncologist, National Cancer Institute - IRCCS Foundation, Milan, Italy
/attachment.e-eso.net/48/682.jpg)
Hammersmith Campus, London, United Kingdom
/attachment.e-eso.net/48/2021050608200220.jpg)
Université de Lausanne, CHUV, Lausanne, Switzerland
/attachment.e-eso.net/48/2021053110393239.jpg)
City of Health and Science University Hospital of Turin, Turin, Italy
/attachment.e-eso.net/48/71.jpg)
University Hospital, Zurich, Switzerland
/attachment.e-eso.net/48/2021042309312899.jpg)
Consultant Medical Oncologist, UCL Cancer Institute, London, United Kingdom
/attachment.e-eso.net/48/2021111204444203.jpg)
Leiden University Medical Center, Leiden, The Netherlands
/attachment.e-eso.net/48/911.jpg)
Erasmus M.C. Cancer Center, Rotterdam, The Netherlands
/attachment.e-eso.net/48/2021101902163185.jpg)
Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland
An ESO-ESMO-RCE joint event
In partnership with
In collaboration with
